Year: 2025

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET). A live webcast will be available on the Presentations portion of Entrada’s Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event. About Entrada TherapeuticsEntrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed...

FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing (NGS)-based gene mutation analysis with the combination of DecisionDx-UM and Preferentially Expressed Antigen in Melanoma (PRAME) gene expression for predicting outcomes in patients with uveal melanoma (UM). The study, titled “Early Genetic Evolution of Driver Mutations in Uveal Melanoma,” was conducted by the Collaborative Ocular Oncology Group (COOG) and recently published in Nature Communications. “The recently published COOG2 study validated that combining DecisionDx-UM test results and PRAME gene expression data provides more precise...

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:45am PST/12:45pm EST. The live webcast will be available under the “Events & Presentations” tab on the “Investors” page of the Company’s website on the day of the event. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer....

WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) — EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. PT/10:30 a.m. ET. A webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepoint.bio. About EyePoint EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s...

NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Cabral Gold Inc. (TSX-V: CBR; OTCQX: CBGZF), a junior resource company, has qualified to trade on the OTCQX® Best Market. Cabral Gold Inc. upgraded to OTCQX from the OTCQB® Venture Market. Cabral Gold Inc. begins trading today on OTCQX under the symbol “CBGZF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating...

Leucipa™, FusionPro™ integration will optimize ESP operations Agreement follows third-quarter award for advanced wireline, perforation technologyHOUSTON and LONDON, Dec. 17, 2025 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR), an energy technology company, announced Wednesday a major award from Kuwait Oil Company (KOC) to provide advanced artificial lift systems and associated services to enhance production in Kuwait’s oil and gas fields. Under the multi-year agreement, Baker Hughes will supply its portfolio of electrical submersible pumps (ESPs), as well as installation, surveillance and maintenance services. ESP performance will be further optimized through the integration of the FusionPro™ intelligent production drive and Leucipa™ automated field production solution, which will enhance operational...

ROUYN-NORANDA, Quebec, Dec. 17, 2025 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) (OTCQB: ABMBF) is pleased to present an update on the November development work at the Sleeping Giant Mine, located in the Eeyou Istchee region of Quebec. HighlightsTonnes milled: 1,346 tonnesMill Head Grade: 7.2 g/t% Recovered: 95.8%Ounces Produced: 298 ouncesOunces Poured: 425 ouncesAbcourt advanced the development of its workplaces and continued hiring in November. Abcourt added a fourth mining front as planned. The lower tonnage in November was caused by development sequence in two of the four workplaces.   It was a question of timing to safely advance the workplaces like advancing ventilation to the next sub-level in one of the workplaces.   During a startup, sequencing has a greater...

License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applications Collaboration supports Sagimet’s fixed-dose combination (FDC) program currently in clinical development Sagimet’s Phase 1 pharmacokinetic (PK) trial of combination of denifanstat and resmetirom is underway with topline data anticipated by the end of 2025 Sagimet anticipates selecting one of the innovative forms of resmetirom licensed from TAPI for combination with denifanstat in a fixed dose combination (FDC) tablet for use in Phase 3SAN MATEO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

Design phase contract is with a European specialist in radioactive waste processing and nuclear decommissioning MONTREAL, Dec. 17, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today the recent signing of an initial design phase contract with a European organization specializing in radioactive waste processing and nuclear decommissioning. As previously reported in the Outlook section of PyroGenesis’ 2nd quarter earnings report, PyroGenesis was in negotiations with a major European entity for the use of plasma in the destruction of low-level radioactive waste. The contract announced today is for a design phase contract toward...

SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 from 5:15 PM to 5:55 PM Pacific Time. Additionally, Biomea’s management team will host one-on-one meetings throughout the conference, which will take place from January 12-15. A live audio webcast of the presentation can be accessed here or by visiting the Investors & Media section of Biomea’s website at https://investors.biomeafusion.com/news-events/events. A replay of the webcast will be available following the live presentation. About Biomea FusionBiomea Fusion is a clinical-stage biopharmaceutical...